INSM
NASDAQ · Biotechnology
Insmed Inc
$98.61
+2.81 (+2.93%)
Financial Highlights (FY 2026)
Revenue
660.47M
Net Income
-1,390,575,496
Gross Margin
79.7%
Profit Margin
-210.5%
Rev Growth
+35.2%
D/E Ratio
0.99
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 79.7% | 79.7% | 43.9% | 43.9% |
| Operating Margin | -205.6% | -185.0% | 2.8% | 3.5% |
| Profit Margin | -210.5% | -200.0% | 2.4% | 3.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 660.47M | 488.51M | 44.36B | 43.93B |
| Gross Profit | 526.59M | 389.49M | 19.46B | 19.27B |
| Operating Income | -1,357,853,001 | -903,896,228 | 1.25B | 1.55B |
| Net Income | -1,390,575,496 | -925,678,954 | 1.08B | 1.36B |
| Gross Margin | 79.7% | 79.7% | 43.9% | 43.9% |
| Operating Margin | -205.6% | -185.0% | 2.8% | 3.5% |
| Profit Margin | -210.5% | -200.0% | 2.4% | 3.1% |
| Rev Growth | +35.2% | +35.2% | +19.4% | +5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 5.15B | 5.15B | 8.61B | 10.21B |
| Total Equity | 5.23B | 5.23B | 24.15B | 26.36B |
| D/E Ratio | 0.99 | 0.99 | 0.36 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,351,364,973 | -949,553,790 | 2.00B | 1.93B |
| Free Cash Flow | — | — | 843.11M | 852.61M |